Review



fak inhibitor defactinib  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    MedChemExpress fak inhibitor defactinib
    Fak Inhibitor Defactinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/Defactinib/pm41922310-92-1-33
    Average 95 stars, based on 70 article reviews
    fak inhibitor defactinib - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: Non-enzymatic function of QSOX2 directly regulates the JUNB-ITGB4 axis and enhanced resistance to osimertinib in EGFR-mutation lung adenocarcinoma.
    Article Snippet: The FAK inhibitor Defactinib (Cat. No.VS-6063; HY-12289), the FAK agonist ZINC40099027 (Cat. No. HY-134570), the AKT inhibitor Capivasertib (AZD5363; Cat. No. HY-15431), and the MEK inhibitor U0126 (Cat. No. HY-12031A) were purchased from MedChemExpress (MCE).

    Article Title: Non-enzymatic function of QSOX2 directly regulates the JUNB-ITGB4 axis and enhanced resistance to osimertinib in EGFR-mutation lung adenocarcinoma
    Article Snippet: The FAK inhibitor Defactinib (Cat. No.VS-6063; HY-12289), the FAK agonist ZINC40099027 (Cat. No. HY-134570), the AKT inhibitor Capivasertib (AZD5363; Cat. No. HY-15431), and the MEK inhibitor U0126 (Cat. No. HY-12031A) were purchased from MedChemExpress (MCE).

    Article Title: Angptl5 restricts primitive hematopoiesis by modulating retinoic acid signaling in zebrafish
    Article Snippet: Detailed pharmacological parameters and experimental concentrations are tabulated below: Retinoic acid (RA) (sigma), Aldehyde dehydrogenase inhibitors 4-diethylaminobenzaldehyde (DEAB) (MCE, 10 μM), Retinoic acid receptor (RARs) antagonists AGN 193109 (MCE, 20 μM), FAK inhibitor Defactinib (MCE, 2 μM /8 μM), MAPK inhibitor Adezmapimod (MCE, 10 μM), ERK inhibitor Mirdametinib (MCE, 10 μM), ERK activator C16-PAF (MCE, 1 μM /5 μM), NF-κB inhibitor BAY 11-7082 (MCE, 0.1 μg/mL, 0.4 μg/mL).

    Wound Healing Assay:

    Article Title: TBX3 reciprocally controls key trophoblast lineage decisions in villi during human placenta development in the first trimester.
    Article Snippet: Human trophoblastic lineage development is intertwined with placental development and pregnancy outcomes, but the regulatory mechanisms underpinning this process remain inadequately understood.. In this study, based on single-nuclei RNA sequencing (snRNA-seq) analysis of the human early maternal-fetal interface, we compared the gene expression pattern of trophoblast at different developmental stages.. Our findings reveal a predominant upregulation of TBX3 during the transition from villous cytotrophoblast (VCT) to syncytiotrophoblast (SCT), but downregulation of TBX3 as VCT progresses into extravillous trophoblast cells (EVT).

    In Vitro:

    Article Title: Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone
    Article Snippet: The murine RANKL recombinant protein (Peprotech, 315-11) and the murine M-CSF recombinant protein (Peprotech, 315-02) were used in this study. .. The FAK inhibitor Defactinib for in vitro assay (2 μM) was obtained from MedChemExpress (HY-12289). ..

    Positive Control:

    Article Title: Demethylzeylasteral attenuates hepatic stellate cell activation and liver fibrosis by inhibiting AGAP2 mediated signaling.
    Article Snippet: Background: Liver fibrosis is a common cause of chronic liver disease.. If left untreated, it can ultimately develop into liver cirrhosis or hepatocellular carcinoma.. However, a direct antifibrotic therapy is currently unavailable.



    Similar Products

    95
    MedChemExpress fak inhibitor defactinib
    Fak Inhibitor Defactinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/Defactinib/pm41922310-92-1-33
    Average 95 stars, based on 1 article reviews
    fak inhibitor defactinib - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    86
    Verastem Inc small molecule fak inhibitor defactinib
    Small Molecule Fak Inhibitor Defactinib, supplied by Verastem Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/defactinib+fak+inhibitor/pm41796449-0-8-7
    Average 86 stars, based on 1 article reviews
    small molecule fak inhibitor defactinib - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Pfizer Inc focal adhesion kinase fak inhibitor defactinib
    Focal Adhesion Kinase Fak Inhibitor Defactinib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/erbb+inhibitor+kinase+pan/10__3390_slash_biom16030381-107-2-16
    Average 86 stars, based on 1 article reviews
    focal adhesion kinase fak inhibitor defactinib - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Verastem Inc focal adhesion kinase fak inhibitor defactinib
    Structures of avutometinib ( 41 ) and <t>defactinib</t> ( 42 ).
    Focal Adhesion Kinase Fak Inhibitor Defactinib, supplied by Verastem Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/defactinib+fak+inhibitor/pmc13023470-108-2-22
    Average 86 stars, based on 1 article reviews
    focal adhesion kinase fak inhibitor defactinib - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    95
    Selleck Chemicals atp competitive fak pyk2 inhibitor vs 6063
    Structures of avutometinib ( 41 ) and <t>defactinib</t> ( 42 ).
    Atp Competitive Fak Pyk2 Inhibitor Vs 6063, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/Defactinib/pm41576481-175-12-17
    Average 95 stars, based on 1 article reviews
    atp competitive fak pyk2 inhibitor vs 6063 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress fak inhibitor
    Structures of avutometinib ( 41 ) and <t>defactinib</t> ( 42 ).
    Fak Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fak+inhibitor+defactinib/Defactinib/10__1096_slash_fj__202500347r-66-24-31
    Average 95 stars, based on 1 article reviews
    fak inhibitor - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Structures of avutometinib ( 41 ) and defactinib ( 42 ).

    Journal: Biomolecules

    Article Title: Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules

    doi: 10.3390/biom16030381

    Figure Lengend Snippet: Structures of avutometinib ( 41 ) and defactinib ( 42 ).

    Article Snippet: The ATP-competitive focal adhesion kinase (FAK) inhibitor defactinib, often referred to as VS-6063, was developed by Pfizer and is currently owned by Verastem [ ].

    Techniques:

    Preparation of defactinib ( 42 ).

    Journal: Biomolecules

    Article Title: Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules

    doi: 10.3390/biom16030381

    Figure Lengend Snippet: Preparation of defactinib ( 42 ).

    Article Snippet: The ATP-competitive focal adhesion kinase (FAK) inhibitor defactinib, often referred to as VS-6063, was developed by Pfizer and is currently owned by Verastem [ ].

    Techniques:

    Experimental bound conformation of defactinib (PDB: 5MAH ; crystal structure of MELK in complex with defactinib). Defactinib is depicted as thick green sticks, MELK is represented by cyan cartoons and thin sticks. H-bonds are represented by yellow dashed lines.

    Journal: Biomolecules

    Article Title: Halogen-Containing Drugs in 2025: A Record Year for the Therapeutic Use and Synthesis of FDA-Approved Small Molecules

    doi: 10.3390/biom16030381

    Figure Lengend Snippet: Experimental bound conformation of defactinib (PDB: 5MAH ; crystal structure of MELK in complex with defactinib). Defactinib is depicted as thick green sticks, MELK is represented by cyan cartoons and thin sticks. H-bonds are represented by yellow dashed lines.

    Article Snippet: The ATP-competitive focal adhesion kinase (FAK) inhibitor defactinib, often referred to as VS-6063, was developed by Pfizer and is currently owned by Verastem [ ].

    Techniques: